| PD-1 controls follicular T helper cell positioning and function J Shi, S Hou, Q Fang, X Liu, X Liu, H Qi Immunity 49 (2), 264-274. e4, 2018 | 430 | 2018 |
| The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation R Chen, Y Zou, D Mao, D Sun, G Gao, J Shi, X Liu, C Zhu, M Yang, W Ye, ... Journal of Cell Biology 206 (2), 173-182, 2014 | 222 | 2014 |
| Germinal-center development of memory B cells driven by IL-9 from follicular helper T cells Y Wang, J Shi, J Yan, Z Xiao, X Hou, P Lu, S Hou, T Mao, W Liu, Y Ma, ... Nature immunology 18 (8), 921-930, 2017 | 197 | 2017 |
| Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study L Shen, K Kato, SB Kim, JA Ajani, K Zhao, Z He, X Yu, Y Shu, Q Luo, ... Journal of clinical oncology 40 (26), 3065-3076, 2022 | 187 | 2022 |
| CapZ regulates autophagosomal membrane shaping by promoting actin assembly inside the isolation membrane N Mi, Y Chen, S Wang, M Chen, M Zhao, G Yang, M Ma, Q Su, S Luo, ... Nature cell biology 17 (9), 1112-1123, 2015 | 154 | 2015 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global … J Xu, K Kato, E Raymond, RA Hubner, Y Shu, Y Pan, SR Park, L Ping, ... The Lancet Oncology 24 (5), 483-495, 2023 | 115 | 2023 |
| B-cell-specific checkpoint molecules that regulate anti-tumour immunity L Bod, YC Kye, J Shi, E Torlai Triglia, A Schnell, J Fessler, SM Ostrowski, ... Nature 619 (7969), 348-356, 2023 | 75 | 2023 |
| Plexin B2 and semaphorin 4C guide T cell recruitment and function in the germinal center H Yan, L Wu, C Shih, S Hou, J Shi, T Mao, W Chen, B Melvin, RJ Rigby, ... Cell reports 19 (5), 995-1007, 2017 | 53 | 2017 |
| Checkpoint receptor TIGIT expressed on Tim-1+ B cells regulates tissue inflammation S Xiao, L Bod, N Pochet, SB Kota, D Hu, A Madi, J Kilpatrick, J Shi, A Ho, ... Cell reports 32 (2), 2020 | 52 | 2020 |
| LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for … H Yoon, K Kato, E Raymond, R Hubner, Y Shu, Y Pan, Y Jiang, J Zhang, ... Annals of Oncology 33, S375, 2022 | 27 | 2022 |
| Virtual memory T cells orchestrate extralymphoid responses conducive to resident memory S Hou, T Shao, T Mao, J Shi, J Sun, M Mei, X Tan, H Qi Science Immunology 6 (62), eabg9433, 2021 | 22 | 2021 |
| Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors D Ye, J Desai, J Shi, SYM Liu, W Shen, T Liu, Y Shi, D Wang, L Liang, ... Biomarker Research 11 (1), 25, 2023 | 7 | 2023 |
| AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced … R Xu, SB Kim, D Tougeron, Y Zuo, H Yang, J Zhang, J Shi, E Van Cutsem Journal of Clinical Oncology 39 (15_suppl), TPS4150-TPS4150, 2021 | 5 | 2021 |
| AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced … R Xu, SB Kim, D Tougeron, Y Zuo, H Yang, J Zhang, J Shi, E Van Cutsem Journal of Clinical Oncology 40 (4_suppl), TPS370-TPS370, 2022 | 3 | 2022 |
| Neuropeptide signalling orchestrates T cell differentiation Y Hou, L Sun, MW LaFleur, L Huang, C Lambden, PI Thakore, ... Nature, 1-9, 2024 | 2 | 2024 |
| Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup … J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, ... ESMO open 9 (1), 102202, 2024 | 2 | 2024 |
| 79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC) J Xu, N Xu, Y Bai, L Chia-Chi, M Millward, J Shi, Y Zhang, X Ma, Z Shen, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), A86-A86, 2020 | 2 | 2020 |
| Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous … Y Shu, J Wang, Z Chen, SB Kim, CY Lin, K Kato, E Van Cutsem, W Du, ... Journal of Clinical Oncology 42 (3_suppl), 390-390, 2024 | 1 | 2024 |
| 395MO Tislelizumab (TIS)+ chemotherapy (CT) vs placebo (PBO)+ CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 E Raymond, J Xu, K Kato, R Hubner, Y Shu, SR Park, T Kojima, ... Annals of Oncology 35, S159, 2024 | | 2024 |
| Concordance Among Three Programmed Death-Ligand 1 Scoring Methods and Their Association With Clinical Outcomes of Tislelizumab Monotherapy in Esophageal Squamous Cell Carcinoma Y Shu, J Wang, Z Chen, SB Kim, CY Lin, K Kato, E Van Cutsem, W Du, ... TC 1 (116), 33, 2024 | | 2024 |
